Company intelligence / Profile preview

Lario Therapeutics

Edinburgh, Scotland, United Kingdomlariotx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Developing first-in-class, orally active, CNS-penetrant CaV2.3 ion channel inhibitors that show promise as anti-seizure therapeutics for multiple treatment-resistant epilepsy subtypes[7]

Therapeutic areas: Neurology
Modalities: Small molecules (ion channel inhibitors)
Industry: Biotech

Drug pipeline

1 asset

CaV2.3 ion channel inhibitor

Pre-clinical

Indications: Drug Resistant Epilepsy, CDKL5 Deficiency Disorder, Parkinson's Disease

Beyond the preview

Go deeper on Lario Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lario Therapeutics.

Explore the full profile